| Assessment Status |
Awaiting response from Applicant |
| HTA ID |
22021 |
| Drug |
Ciltacabtagene autoleucel |
| Brand |
Carvykti® |
| Indication |
For the treatment of adult patients with relapsed or refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody and have demonstrated disease progression on the last therapy. |
| Rapid review commissioned |
11/04/2022 |
| Rapid review completed |
12/05/2022 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of cilta-cel (ciltacabtagene autoleucel) compared with the current standard-of-care. |
| Full pharmacoeconomic assessment commissioned by HSE |
27/05/2022 |
| Pre-submission consultation with Applicant |
12/07/2022 |
| Full submission received from Applicant |
30/11/2022 |
| Preliminary review sent to Applicant |
30/05/2023 |
